Aclaris Therapeutics, Inc.
Clinical trials sponsored by Aclaris Therapeutics, Inc., explained in plain language.
A biopharmaceutical company focused on dermatology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New pill shows promise for tough eczema in small study
Disease control CompletedThis study tested an experimental oral drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the pill twice daily for 12 weeks. Researchers tracked safety, side effects, and skin improvement using standard eczema scores. The goal …
Phase 2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for painful skin condition
Disease control CompletedThis study tested an experimental drug called ATI-450 in 95 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The goal was to see if the drug reduces the number of abscesses and inflamed nodules compared to a placebo ove…
Phase 2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC